Abstract Objectives Sarcoidosis is a multisystem granulomatous disorder, and pulmonary fibrosis develops in 5-20% of cases. However, data on the prevalence and clinical characteristics of sarcoidosis-associated pulmonary fibrosis (SAPF) in the Chinese population remain scarce. This study aimed to determine the prevalence of SAPF and related progressive pulmonary fibrosis (PPF) in a large Chinese cohort and to identify potential risk factors associated with fibrosis development. Methods This ambispective cohort included 586 consecutive Chinese Han patients with sarcoidosis diagnosed at Beijing Chaoyang Hospital between January 2013 and June 2024, with follow-up through June 2025. Demographic, clinical, and laboratory data were compared between SAPF and non-SAPF patients. The cumulative incidence of PPF was estimated, and multivariate logistic regression was used to identify independent predictors of SAPF. Results Among 547 eligible patients from 22 provinces across China, 47 (8. 6%) met the diagnostic criteria for SAPF. The median follow-up was 26 months. The cumulative incidences of PPF among SAPF patients were 3%, 26%, and 54% at 1, 3, and 5 years, respectively. Compared with non-SAPF patients, those with SAPF were significantly older and exhibited lower FVC% predicted, lower DLCOSB% predicted, and a higher prevalence of comorbidities. In multivariate analysis, autoimmune diseases (OR 4. 04, 95% CI 1. 27-12. 86; P = 0. 018), coronary heart disease (OR 2. 71, 95% CI 1. 01-7. 29; P = 0. 027), and older age (OR 1. 04, 95% CI 1. 00-1. 07; P = 0. 040) were independently associated with SAPF. Conclusions SAPF was identified in 8. 6% of patients with sarcoidosis in this large multicenter Chinese cohort. Autoimmune comorbidities, coronary heart disease, and advanced age were independent risk factors for fibrosis development. This abstract is funded by: Beijing High-level Public Health Talent Construcion Project
Ye et al. (Fri,) studied this question.